Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Apelin
/ analysis
Body Mass Index
Breast
/ pathology
Breast Neoplasms
/ complications
Chemotherapy, Adjuvant
/ statistics & numerical data
Female
Humans
Mastectomy
Middle Aged
Neoadjuvant Therapy
/ methods
Obesity
/ complications
Retrospective Studies
Treatment Outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 05 2021
10 05 2021
Historique:
received:
16
12
2020
accepted:
26
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Obesity is a known factor increasing the risk of developing breast cancer and reducing disease free survival. In addition to these well-documented effects, recent studies have shown that obesity is also affecting response to chemotherapy. Among the multiple dysregulations associated with obesity, increased level of the apelin adipokine has been recently shown to be directly involved in the association between obesity and increased breast cancer progression. In this study, we analyzed in a retrospective cohort of 62 breast cancer patients the impact of obesity and tumoral apelin expression on response to neoadjuvant chemotherapy. In the multivariate logistic regression, obesity and high tumoral apelin expression were associated with a reduced response to NAC in our cohort. However, obesity and high tumoral apelin expression were not correlated, suggesting that those two parameters could be independently associated with reduced NAC response. These findings should be confirmed in independent cohorts.
Identifiants
pubmed: 33972642
doi: 10.1038/s41598-021-89385-z
pii: 10.1038/s41598-021-89385-z
pmc: PMC8110990
doi:
Substances chimiques
APLN protein, human
0
Apelin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9922Références
Eur J Cancer. 2016 Oct;66:153-61
pubmed: 27573429
EMBO Mol Med. 2019 Aug;11(8):e9266
pubmed: 31267692
Cell Metab. 2008 Nov;8(5):437-45
pubmed: 19046574
Endocrinology. 2005 Apr;146(4):1764-71
pubmed: 15677759
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
J Clin Oncol. 2020 Sep 1;38(25):2883-2891
pubmed: 32614702
Breast Care (Basel). 2011;6(2):136-141
pubmed: 21633630
J Mol Endocrinol. 2013 Nov 26;51(3):T51-9
pubmed: 24163427
Curr Pathobiol Rep. 2017;5(4):315-322
pubmed: 29188139
J BUON. 2013 Apr-Jun;18(2):335-41
pubmed: 23818343
Trends Endocrinol Metab. 2020 Aug;31(8):551-560
pubmed: 32600959
Compr Physiol. 2017 Dec 12;8(1):407-450
pubmed: 29357134
Cancer Biother Radiopharm. 2017 May;32(4):133-138
pubmed: 28514205
Front Oncol. 2017 May 26;7:110
pubmed: 28603694
J Endocrinol. 2013 Sep 11;219(1):R13-35
pubmed: 23943882
Mol Cancer Res. 2019 Jun;17(6):1378-1390
pubmed: 30858172
Medicine (Baltimore). 2018 Jul;97(29):e11433
pubmed: 30024516
Oncotarget. 2017 Jun 27;8(26):42949-42961
pubmed: 28487489
BMC Cancer. 2016 Oct 12;16(1):794
pubmed: 27733135
J Cell Mol Med. 2020 Sep;24(17):10233-10244
pubmed: 32681609
Obes Facts. 2013;6(1):57-69
pubmed: 23429279
Breast Cancer. 2021 May;28(3):618-629
pubmed: 33387284
Breast. 2017 Apr;32:237-244
pubmed: 27318645
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):671-682
pubmed: 29844585
PLoS One. 2013 Jun 27;8(6):e67349
pubmed: 23826274
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848
pubmed: 32046998
Clin Exp Med. 2015 Feb;15(1):97-105
pubmed: 24469934
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
J Clin Invest. 1990 Nov;86(5):1503-10
pubmed: 2243127
Cancer Causes Control. 2016 Feb;27(2):229-36
pubmed: 26621544